Denosumab in breast cancer patients receiving aromatase inhibitors: A single-center observational study of effectiveness in adjuvant setting.
- Resource Type
- letter
- Authors
- Irelli, Azzurra; Sirufo, Maria; Scipioni, Teresa; Pietro, Francesca; Pancotti, Amedeo; Ginaldi, Lia; De Martinis, Massimo; Sirufo, Maria Maddalena; Pietro, Francesca De
- Source
- Indian Journal of Cancer. Jan-Mar2021, Vol. 58 Issue 1, p136-139. 4p.
- Subject
- *AROMATASE inhibitors
*BONE fractures
*BREAST cancer
*CANCER patients
*DENOSUMAB
*BREAST tumors
- Language
- ISSN
- 0019-509X
Successes obtained in the treatment of women with breast cancer have also taught us the importance of simultaneously taking care of their bone health. The safety analysis showed that treatment with denosumab during therapy with AI is well tolerated; no patient discontinued the treatment for limiting toxicity, in particular no musculoskeletal symptoms associated with aromatase inhibitors of degree >=3 were recorded. [Extracted from the article]